Fulcrum Therapeutics, Inc. Common Stock
FULCFulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address genetically defined diseases. The company leverages its gene control platform to identify and develop treatments aimed at restoring or modulating gene expression to improve patient outcomes.
Company News
Fulcrum Therapeutics reported positive Phase 1b trial results for pociredir, an oral medication for sickle cell disease, showing significant increases in fetal hemoglobin and promising safety profile at the 20 mg dose level.
Biohaven's pipeline candidate, troriluzole, met the primary endpoint in a pivotal study for the treatment of spinocerebellar ataxia, a rare neurological disease. The study showed a 50-70% delay in disease progression compared to untreated patients.
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
These recent winners still have a long way to run.
